VRML vs. ACHV, BVS, SBTX, MGTX, NLTX, CLOV, AVIR, ORGO, VMD, and NAUT
Should you be buying Vermillion stock or one of its competitors? The main competitors of Vermillion include Achieve Life Sciences (ACHV), Bioventus (BVS), Silverback Therapeutics (SBTX), MeiraGTx (MGTX), Neoleukin Therapeutics (NLTX), Clover Health Investments (CLOV), Atea Pharmaceuticals (AVIR), Organogenesis (ORGO), Viemed Healthcare (VMD), and Nautilus Biotechnology (NAUT). These companies are all part of the "medical" sector.
Vermillion (NASDAQ:VRML) and Achieve Life Sciences (NASDAQ:ACHV) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, community ranking, valuation and institutional ownership.
18.1% of Vermillion shares are held by institutional investors. Comparatively, 33.5% of Achieve Life Sciences shares are held by institutional investors. 4.4% of Vermillion shares are held by insiders. Comparatively, 2.0% of Achieve Life Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Achieve Life Sciences received 125 more outperform votes than Vermillion when rated by MarketBeat users. Likewise, 70.15% of users gave Achieve Life Sciences an outperform vote while only 66.67% of users gave Vermillion an outperform vote.
Vermillion has a beta of 3.47, meaning that its stock price is 247% more volatile than the S&P 500. Comparatively, Achieve Life Sciences has a beta of 1.26, meaning that its stock price is 26% more volatile than the S&P 500.
In the previous week, Achieve Life Sciences had 2 more articles in the media than Vermillion. MarketBeat recorded 2 mentions for Achieve Life Sciences and 0 mentions for Vermillion. Achieve Life Sciences' average media sentiment score of 0.39 beat Vermillion's score of 0.00 indicating that Achieve Life Sciences is being referred to more favorably in the news media.
Achieve Life Sciences has a consensus target price of $17.25, suggesting a potential upside of 264.31%. Given Achieve Life Sciences' higher probable upside, analysts clearly believe Achieve Life Sciences is more favorable than Vermillion.
Achieve Life Sciences has a net margin of 0.00% compared to Vermillion's net margin of -307.31%. Vermillion's return on equity of -155.25% beat Achieve Life Sciences' return on equity.
Vermillion has higher revenue and earnings than Achieve Life Sciences.
Summary
Achieve Life Sciences beats Vermillion on 9 of the 15 factors compared between the two stocks.
Get Vermillion News Delivered to You Automatically
Sign up to receive the latest news and ratings for VRML and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VRML and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Vermillion Competitors List
Related Companies and Tools
